Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
BeOne Medicines
Eli Lilly and Company
Pheast Therapeutics
ALX Oncology Inc.
R-Pharm
Dispatch Biotherapeutics
Context Therapeutics Inc.
Kivu Bioscience Inc.
NiKang Therapeutics, Inc.
Novartis
EMD Serono
Bayer
Kumquat Biosciences Inc.
Seagen Inc.
Seagen Inc.
Seagen Inc.
Seagen Inc.
Pliant Therapeutics, Inc.
Pfizer
Eli Lilly and Company
Eli Lilly and Company
Pfizer
BioNTech SE
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
BeOne Medicines
Bristol-Myers Squibb
MOMA Therapeutics
Eli Lilly and Company
Pheon Therapeutics
Eli Lilly and Company
AstraZeneca
Novartis
Kivu Bioscience Inc.
Genentech, Inc.
AstraZeneca
Exelixis
Bayer
MOMA Therapeutics
SystImmune Inc.
Astellas Pharma Inc
Incyte Corporation
Kura Oncology, Inc.
Boehringer Ingelheim
Zymeworks BC Inc.
Hoffmann-La Roche
Novartis
AbbVie
Zhejiang Doer Biologics Co., Ltd.